KADCYLA
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Recent trial shows greater invasive disease-free survival when treated with Kadcyla , (ado-trastuzumab emtansine)
1/4 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast…
1/3 Roche’s Kadcyla reduced the risk of disease recurring in people with HER2positive early breast cancer with residual disease…
Recent estimate revealed that in the year 2012, about 227,000 American women suffered from metastatic breast cancer (mBC). The U…
A drug for metastatic breast cancer should not be used in the NHS in England because it is not effective enough to justify its…
Approximately 25% of women who are diagnosed with breast cancer have HER2-positive tumors. The HER2 gene, which resides on…
The FDA has approved ado-trastuzumab emtansine (Kadcyla), known as T-DM1 in development, for the treatment of women with…